Motif Bio PLC Company to present at conferences in September
August 31 2017 - 7:00AM
RNS Non-Regulatory
TIDMMTFB
Motif Bio PLC
31 August 2017
Motif Bio plc
("Motif" or the "Company")
Motif Bio to present at upcoming investor and scientific
conferences
Motif Bio plc (AIM/NASDAQ: MTFB), the clinical stage
biopharmaceutical company specialising in developing novel
antibiotics, announced today that the Company will present at the
following conferences in September.
Rodman & Renshaw 19(th) Annual Global Investment
Conference
September 10-12, 2017
New York, NY USA
Management will provide a corporate overview on Monday,
September 11(th) at 11:15 AM ET. The presentation will be webcast,
available live, and as a replay in the Investors section of the
Company's website.
The conference is expected to feature approximately 200 public
and private companies presenting their businesses to an audience of
approximately 2,000 attendees. Motif will also participate in
one-on-one meetings during the event.
World Anti-Microbial Resistance Congress
September 14-15, 2017
Washington, DC USA
David Huang, MD, PhD, Chief Medical Officer of Motif Bio, will
deliver the luncheon keynote address on September 15(th) . His talk
is entitled: Iclaprim: a well differentiated, targeted, potent and
rapidly bactericidal antibiotic against multidrug resistant
bacteria.
The congress provides a platform for change on both the
scientific and economic sides of the antimicrobial resistance
space, bringing the leaders from each area together to take steps
toward finding collaborative solutions that optimize the best of
both worlds. The event gathers key stakeholders from government,
funding agencies, pharma, academia, hospitals, and payers.
For further information please contact:
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief
Executive Officer)
Robert Dickey IV (Chief
Financial Officer)
Walbrook PR Ltd. (FINANCIAL +44 (0) 20 7933 8780 or
PR & IR) motifbio@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Mike Wort Mob: +44 (0)7900 608 002
MC Services AG (EUROPEAN
IR) +49 (0)89 210 2280
Raimund Gabriel raimund.gabriel@mc-services.eu
The Trout Group (US
IR) +1 (646 )378-2938
Michael Gibralter mgibralter@troutgroup.com
Notes to Editors
About Motif Bio
Motif Bio plc (AIM/NASDAQ: MTFB) is a clinical-stage
biopharmaceutical company engaged in the research and development
of novel antibiotics designed to be effective against serious and
life-threatening infections in hospitalised patients caused by
multi-drug resistant bacteria, including MRSA
(methicillin-resistant Staphylococcus aureus). The Company's lead
product candidate, iclaprim, is being developed for high-risk MRSA
patient populations. The first proposed indication, and near-term
commercial opportunity, is for the treatment of acute bacterial
skin and skin structure infections (ABSSSI), one of the most common
bacterial infections, with 3.6 million patients hospitalised
annually in the U.S. The Company believes that iclaprim is suitable
for first-line empiric therapy in ABSSSI patients, especially those
with renal impairment, with or without diabetes, due to its
underutilised mechanism of action, targeted spectrum of activity,
low propensity for resistance development, fixed dose
administration, clearance of inactive metabolites through the
kidneys and favourable tolerability profile. The Company also plans
to develop iclaprim for hospital acquired bacterial pneumonia
(HABP), including ventilator associated bacterial pneumonia (VABP),
as there is a high unmet need for new therapies in this indication
and iclaprim has demonstrated initial evidence of efficacy in a
Phase 2 trial in patients with HABP. Additionally, in a clinical
study evaluating the tissue distribution of an IV dose of Iclaprim
in relevant lung compartments, high concentrations were found in
epithelial lining fluid and alveolar macrophages, achieving levels
up to 20- and 40-fold higher, respectively, than in plasma.
Iclaprim has been studied in an animal model of chronic pulmonary
MRSA infection which mimics the pathophysiology observed in
patients with cystic fibrosis. Data will be presented at ID Week in
October 2017. Iclaprim has received Qualified Infectious Disease
Product (QIDP) designation from the FDA together with Fast Track
status. Upon acceptance of the NDA, iclaprim will receive Priority
Review status and, if approved as a New Chemical Entity, will be
eligible for 10 years of market exclusivity in the U.S. from the
date of first approval under the Generating Antibiotic Incentives
Now Act (the GAIN Act). In Europe, 10 years of data exclusivity is
anticipated.
Forward-Looking Statements
This press release contains forward-looking statements. Words
such as "expect," "believe," "intend," "plan," "continue," "may,"
"will," "anticipate," and similar expressions are intended to
identify forward-looking statements. Forward-looking statements
involve known and unknown risks, uncertainties and other important
factors that may cause Motif Bio's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Motif Bio believes that these factors
include, but are not limited to, (i) the timing, progress and the
results of clinical trials for Motif Bio's product candidates, (ii)
the timing, scope or likelihood of regulatory filings and approvals
for Motif Bio's product candidates, (iii) Motif Bio's ability to
successfully commercialise its product candidates, (iv) Motif Bio's
ability to effectively market any product candidates that receive
regulatory approval, (v) Motif Bio's commercialisation, marketing
and manufacturing capabilities and strategy, (vi) Motif Bio's
expectation regarding the safety and efficacy of its product
candidates, (vii) the potential clinical utility and benefits of
Motif Bio's product candidates, (viii) Motif Bio's ability to
advance its product candidates through various stages of
development, especially through pivotal safety and efficacy trials,
(ix) Motif Bio's estimates regarding the potential market
opportunity for its product candidates, and (x) the factors
discussed in the section entitled "Risk Factors" in Motif Bio plc's
Annual Report on Form 20-F filed with the SEC on May 1, 2017, which
is available on the SEC's web site, www.sec.gov. Motif Bio plc
undertakes no obligation to update or revise any forward-looking
statements.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAXPFDLXXEEF
(END) Dow Jones Newswires
August 31, 2017 08:00 ET (12:00 GMT)
Motif Bio (LSE:MTFB)
Historical Stock Chart
From Apr 2024 to May 2024
Motif Bio (LSE:MTFB)
Historical Stock Chart
From May 2023 to May 2024